New cancer drug combo shows early promise in tiny trial

NCT ID NCT07269899

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study is testing a new drug called WTX212A, alone or with radiation, in 12 people with advanced solid tumors. The goal is to see if it shrinks tumors and is safe. It's a small first step to find out if this approach is worth studying further.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WTX212A injection (erythrocyte-αPD-1 antibody conjugate) and radiotherapy
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong: This is a very early phase 1 study with only 12 people, so it's too soon to know if it's safe or effective. Many early-stage cancer trials do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER SOLID TUMOR CANCER

Contacts and locations

Locations

Cancer Center of SUN YAT-senU
RECRUITING

Guangzhou, Guangdong, 510000, China
Cancer center of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.